Peter J. Thornton net worth and biography

Peter Thornton Biography and Net Worth

Director of Avadel Pharmaceuticals

Peter J. Thornton has been a member of the Avadel Board of Directors since June 2017. He is the President and Chief Financial Officer of Envetec Sustainable Technologies Limited, an Irish company that provides technologies to safely treat biohazardous laboratory waste at source while reducing carbon emissions. Peter is also Director of Oculer Limited – an Irish company focused on developing and commercializing proprietary rapid microbiology assays and instruments. Previously, Peter held leadership roles as Chief Financial Officer of Technopath Clinical Diagnostics, an Irish company that provides quality control solutions to clinical laboratories, Senior Vice President - Business Integration for Alkermes plc, and Senior Vice President - Corporate and Business Development for Elan Drug Technologies. In addition, he was previously President and Chief Operating Officer of Circ Pharma Limited, and Chief Financial Officer of Agenus Inc. Peter also worked for the international public accounting firm of KPMG for seven years in Ireland and France and is a fellow of Chartered Accountants Ireland. He holds a Bachelor of Commerce degree from University College Cork, Ireland.

What is Peter J. Thornton's net worth?: The estimated net worth of Peter J. Thornton is at least $977,076.45 as of January 13th, 2025. Mr. Thornton owns 104,055 shares of Avadel Pharmaceuticals stock worth more than $977,076 as of May 8th. This net worth evaluation does not reflect any other investments that Mr. Thornton may own. Learn More about Peter J. Thornton's net worth.
How do I contact Peter J. Thornton?: The corporate mailing address for Mr. Thornton and other Avadel Pharmaceuticals executives is 10 EARLSFORT TERRACE, DUBLIN L2, D02. Avadel Pharmaceuticals can also be reached via phone at (531) 901-5201 and via email at investors@avadel.com. Learn More on Peter J. Thornton's contact information.
Has Peter J. Thornton been buying or selling shares of Avadel Pharmaceuticals?: Peter J. Thornton has not been actively trading shares of Avadel Pharmaceuticals in the last ninety days. Most recently, on Monday, January 13th, Peter J. Thornton bought 10,000 shares of Avadel Pharmaceuticals stock. The stock was acquired at an average cost of $8.04 per share, with a total value of $80,400.00. Following the completion of the transaction, the director now directly owns 104,055 shares of the company's stock, valued at $836,602.20. Learn More on Peter J. Thornton's trading history.
Who are Avadel Pharmaceuticals' active insiders?: Avadel Pharmaceuticals' insider roster includes Gregory Divis (CEO), Geoffrey Glass (Director), Geoffrey Glass (Director), Thomas McHugh (CFO), Linda Palczuk (Director), and Peter Thornton (Director). Learn More on Avadel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Avadel Pharmaceuticals?: During the last twelve months, Avadel Pharmaceuticals insiders bought shares 8 times. They purchased a total of 55,579 shares worth more than $526,363.04. The most recent insider tranaction occured on January, 21st when Director Linda Palczuk bought 5,000 shares worth more than $39,650.00. Insiders at Avadel Pharmaceuticals own 4.8% of the company. Learn More about insider trades at Avadel Pharmaceuticals.
Information on this page was last updated on 1/21/2025.

Peter J. Thornton Insider Trading History at Avadel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/13/2025	Buy	10,000	$8.04	$80,400.00	104,055
9/21/2017	Buy	5,155	$9.74	$50,209.70	5,155

Peter J. Thornton Buying and Selling Activity at Avadel Pharmaceuticals

Avadel Pharmaceuticals Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Today's Range

Now: $9.39

$8.98

$9.77

50 Day Range

MA: $8.04

$6.59

$9.47

2 Week Range

Now: $9.39

$6.38

$17.85

Volume

2,287,557 shs

Average Volume

1,245,511 shs

Market Capitalization

$907.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4